Gsk Share Discussion Threads

[lovewinshatelosses] 30/10/2019 17:33

I am delighted with those results and if I had any further capacity, I would buy more. Must be some broker re-rates coming in the next few days?

[quepassa] 30/10/2019 16:19

Very bullish press over GSK's excellent Q3 Trading Update today, with raised profit forecast and a big rise in T/O,will likely carry share price over 1800p in short order.

[crossing_the_rubicon] 30/10/2019 15:00

2019 guidance.

GSK now expects 2019 Adjusted EPS will be around flat at CER. This new guidance represents a further improvement to that previously given in July 2019 of an expected decline in Adjusted EPS in the range of -3% to -5% at CER. The new guidance reflects operating performance in the nine months, increased investment in R&D and priority assets and a lower expected effective tax rate of around 17% for the year.

[arja] 30/10/2019 14:59

edging up in US market which I suppose lead market after futures opens at about 11.30am Will mirror US price until UK close I suppose , $45.18 -$45.29 at the moment
and creeping slowly higher - go , baby go !

[crossing_the_rubicon] 30/10/2019 14:51

Key product sales:

Shingrix: 535M (+87%);

Ellipta: 603M (+21%);

Bexsero: 255M (+23%);

Fluarix, FluLaval: 371M (+22%);

Nucala: $203M (+40%);



Seretide/Advair: 418M (-32%);


Flixotide/Flovent: 171M (+46%);
Ventolin: 231M (+34%);
Infanrix, Pediarix: 199M (+24%).

[crossing_the_rubicon] 30/10/2019 14:48

GlaxoSmithKline EPS misses by £0.23, beats on revenue
Revenue of £9.39B (+16.1% Y/Y) beats by £430M

Q3 Non-GAAP EPS of £0.39 misses by £0.23;
GAAP EPS of £0.31 misses by £0.18.

GlaxoSmithKline plc 2019 Q3 - Results - Earnings Call Presentation

[tim 3] 30/10/2019 14:47

Come on close over £17.50 you know you want too !

[tradermichael] 30/10/2019 14:32

Emma sounded very inexperienced/nervous - lots of um, erm, er, sort of, I mean, you knows

[tradermichael] 30/10/2019 14:02

Webcast running NOW, live

[spud] 30/10/2019 13:59

Buy on rumour, sell on fact.

Fact!!

spud

[abdullla] 30/10/2019 13:56

Who would have thought that the share price would go down after such results,amazing !

[abdullla] 30/10/2019 13:44

TM your prayers are being answered as I write!

[spud] 30/10/2019 12:51

Crakerjack results!

Dividend hike for fy 2020?

spud

[abdullla] 30/10/2019 12:38

TM yes I hope we are entering a new phase of rising share price reflecting these results,as GSK takes a new position in the market -:)

[tradermichael] 30/10/2019 12:30

I'd like to be IN right now, but I'm not IN!

If there's a serious bout of profit taking following these stunning results, then I'd like to revisit for the dividend then hold, particularly as there's several new products being filed in Q4.

[abdullla] 30/10/2019 12:22

TM yes good results and a lot of profit taking,are you going IN for the divi (:- ?

[tradermichael] 30/10/2019 12:18

Quite euphoric, I reckon ….. ;0)

[tradermichael] 30/10/2019 12:18

GSK delivers sales of GBP9.4 billion +16% AER, +11% CER (Pro-forma
+6% CER*)
Total EPS 31.4p +9% AER, -1% CER; Adjusted EPS 38.6p +9% AER, +1%
CER

[abdullla] 30/10/2019 12:07

Take euphoria with caution twice a day

[quepassa] 30/10/2019 12:05

GSK now at:

- 12 month HIGH

- 3 Year HIGH

- 5 Year HIGH


and heading for ten year high when it breaches 1800p

QP

[abdullla] 30/10/2019 11:58

let us wait for the results first

[quepassa] 30/10/2019 11:54

GSK now at:

- 12 month HIGH

- 3 Year HIGH

- 5 Year HIGH


and heading for ten year high when it breaches 1800p

QP

[tompion] 30/10/2019 09:49

The broken economic model is a very real issue for antibiotic development that needs to be resolved. A major problem is the lack of incentive to produce antibiotics, as any highly effective novel antibiotic will most likely be held back as the drug of last resort, to reduce usage and thus development of drug resistance. Hardly an incentive to develop antibiotics rather drugs used every day for life! There has been a lot of discussion of ways to get around this issue of the broken economic model,to provide incentives for companies to work on antibiotic discovery and development, but not sure whether any of the ideas floated have got anywhere.

[tradermichael] 30/10/2019 09:03

Results today:

It is expected that the positive impact of foreign exchange on Q3 2019 sales will be around +4%.
As a result of the mix of currency movements relative to the mix of costs, expect that the positive impact of foreign exchange on Q3 2019 sterling Adjusted EPS will be greater than the positive impact on sales.

[tradermichael] 29/10/2019 19:04

Broken market or broken logic?

The US Administration is to blame here. Drug companies are loathe to increase any prices under the current climate for fear of incurring the wrath of the Administration and the accusation of 'profiteering'.

The US cannot have it both ways ……. ;0(